Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
Returns on capital
Kodiak Sciences Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-146.1%
avg -47.3%
ROIC
-73.7%
avg -7.6%
ROA
-65.4%
avg -132.5%
Analysis
ROA is currently the strongest return metric at -65.4% versus its period average of -132.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | USD 1.58M | 52 | 0 | <0.01% |
John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | USD 937.16K | 63 | 211.93K | 0.40% |
Hong Liang | Senior Vice President of Development | USD 300.71K | 54 | 130.17K | 0.25% |
J. Pablo Velazquez-Martin | Chief Medical Officer | — | — | — | — |
Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | — | — | — | — |
Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | — | — | — | — |
Almas Qudrat | Chief Quality Officer | — | — | — | — |
Wayne To | Chief Technology Officer | — | — | — | — |
Dolly S. Chang | Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 21, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
88
$241.33M
Sells
14
$4.92M
Net Transaction Value
+$236.41M
Net buying
Most Active
BAKER BROS. ADVISORS LP
88 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $463.3K$463,292.53 |
| Nov 5, 26Nov 5, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $8.1M$8,051,123.79 |
| Nov 4, 26Nov 4, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $861.2K$861,174.42 |
| Nov 4, 26Nov 4, 2026 | BAKER BROS. ADVISORS LP Indirect | Buy | $15M$14,965,245.16 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $273.9K$273,903.60 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $187.4K$187,420.00 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $9.5K$9,491.00 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $746.4K$746,422.38 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $149.6K$149,588.40 |
| Oct 21, 26Oct 21, 2026 | BORGESON JOHN A. Direct | Sell | $684.1K$684,088.02 |
1–10 of 102
Summary
Insiders reported 88 buys worth $241.33M and 14 sells worth $4.92M over the last 12 months. That adds up to net buying of $236.41M. BAKER BROS. ADVISORS LP was the most active insider with 88 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Kodiak Sciences Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KOD's management, answered from reported figures.
Who manages KOD?
Kodiak Sciences Inc. (KOD) lists 9 active executives. The top listed executive is J. Pablo Velazquez-Martin, Chief Medical Officer.
Are KOD insiders buying or selling?
Recent insider activity shows net buying of $266.33M.
Continue the stock analysis
Jump to another research area for this company.